Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

NCT00903175 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

471

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: everolimus
DRUG: sunitinib

Sponsor

Novartis Pharmaceuticals